OncoSec Expands Relationship with Merck, Announces Clinical Collaboration to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Triple Negative Breast Cancer May 8, 2018
OncoSec Announces PISCES/KEYNOTE-695 Trial-in-Progress Poster Presentation at Upcoming ASCO 2018 Annual Meeting April 26, 2018
OncoSec to Host Research Reception During the 2018 American Association of Cancer Research Annual Meeting April 3, 2018
OncoSec's Intratumoral IL-12 In Metastatic Triple Negative Breast Cancer (TNBC) Selected For Oral Poster Presentation At The American Association For Cancer Research (AACR) Annual Meeting 2018 March 15, 2018
OncoSec Announces Publication In Nature Gene Therapy Demonstrating Efficacy Of IL-12 Intratumoral Gene Electrotransfer March 12, 2018
OncoSec Medical Incorporated Announces Closing of $23.0 Million Public Offering of Common Stock February 6, 2018
